For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Insulet Corporation (PODD) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-09-13): Designation Watch · Gem Score -7 (−100…+100 Quality+Value blend) · Quality 58 · Value -50 · Sentiment 0 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Insulet Corporation
PODD NASDAQInsulet Corporation is a medical device company specializing in insulin delivery technologies for people living with insulin‑dependent diabetes. The company focuses on its Omnipod platform, a family of tubeless, wearable, pod-based insulin management systems designed to provide continuous subcutaneous insulin infusion without the need for multiple daily injections. Key offerings include the Omnipod 5 automated insulin delivery system, which incorporates a proprietary algorithm and connects with compatible continuous glucose monitors via Bluetooth, and the Omnipod DASH system, which is controlled through a handheld, smartphone-like device. Insulet also supplies wearable drug-delivery pods for use in certain oncology-related treatments, such as the Neulasta Onpro kit. Products are distributed through the pharmacy channel and independent distributors, serving patients in the United States and international markets. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet today plays a notable role in the healthcare and medical devices sector by providing device-based solutions that support day-to-day diabetes management.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.48
Total Equity: $1.52B
Shares: 71,886,000
Total Debt: $18.40M
Cash: $716.10M
EBITDA: $564.20M
Total Debt: $18.40M
Cash: $716.10M
Revenue: $2.71B
Revenue: $2.71B
Revenue: $2.71B
Total Equity: $1.52B
Tax Rate: 27.2%
Equity: $1.52B
Total Debt: $18.40M
Cash: $716.10M
Current Liabilities: $680.10M
Long-Term Debt: $0.00
Total Debt: $18.40M
Total Equity: $1.52B
Shares: 71,886,000
Shares: 71,886,000
CapEx: -$191.60M
Shares: 71,886,000
Stock Price: $143.34
Net Income: $247.10M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 11:12am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.3B | $1.7B | $2.1B | $2.7B |
| Cost of Revenue | $346.7M | $499.7M | $537.2M | $625.9M | $768.2M |
| Gross Profit | $752.1M | $805.6M | $1.2B | $1.4B | $1.9B |
| Operating Expenses | $626.1M | $768.0M | $939.9M | $1.1B | $1.5B |
| Operating Income | $126.0M | $37.6M | $220.0M | $308.9M | $473.8M |
| Net Income | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M |
| EBITDA | $183.4M | $100.8M | $292.8M | $389.7M | $564.2M |
| EPS | $0.25 | $0.07 | $2.96 | $5.97 | $3.51 |
| EPS (Diluted) | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 10:53am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $806.4M | $689.7M | $704.2M | $953.4M | $716.1M |
| Total Current Assets | $1.3B | $1.3B | $1.6B | $1.9B | $1.9B |
| Total Assets | $2.0B | $2.3B | $2.6B | $3.1B | $3.2B |
| Current Liabilities | $228.8M | $364.7M | $451.2M | $528.4M | $680.1M |
| Long-Term Debt | $1.2B | $1.4B | — | — | — |
| Total Liabilities | $1.5B | $1.8B | $1.9B | $1.9B | $1.7B |
| Total Equity | $556.3M | $476.4M | $732.7M | $1.2B | $1.5B |
| Retained Earnings | -$649.5M | -$584.3M | -$378.0M | $40.3M | $287.4M |
Cash Flow (Annual)
Last updated: Aug 15, 2026 11:12am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$68.1M | $119.0M | $145.7M | $430.3M | $569.3M |
| Capital Expenditure | -$111.9M | -$122.9M | -$75.6M | -$124.9M | -$191.6M |
| Free Cash Flow | -$180.0M | -$3.9M | $70.1M | $305.4M | $377.7M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | $0 | $0 | $440.7M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | $0 | $0 | -$59.6M |
| Net Change in Cash | -$115.6M | -$116.7M | $14.5M | $249.2M | -$237.3M |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 11:12am (29d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +18.8% | +30.0% | +22.1% | +30.7% |
| Gross Profit Growth | +7.1% | +44.0% | +24.6% | +34.2% |
| Operating Income Growth | -70.2% | +485.1% | +40.4% | +53.4% |
| Net Income Growth | -72.6% | +4,384.8% | +102.8% | -40.9% |
| EBITDA Growth | -45.0% | +190.5% | +33.1% | +44.8% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-17 16:18The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw quarterly trajectory is more impressive than the "decelerating" tag suggests. Revenue went from $488M in Q2'24 to $761.7M in Q1'26 — that's 56% growth over seven quarters, with the last four prints ($569, $649, $706, $784, $762) showing sequential acceleration then a modest seasonal dip. Recent YoY is +30.7% and holding. The "earnings deceleration" narrative (-40.9% YoY) is largely a tax/one-time artifact: Q2'24 NI of $188.6M on $488M revenue (38.6% margin) is obviously not a run-rate number — it included a large deferred tax benefit. Strip that and the underlying operating margin trajectory is *expanding*, not compressing: FY22 op margin 2.9% → FY23 12.9% → FY24 14.9% → FY25 17.5%. That's textbook operating leverage on a device-plus-consumables model, not the "structurally challenged pod economics" bear case.
Balance sheet is pristine — $716M cash against $18M debt, D/E of 0.012, current ratio 2.8. ROIC of 42% is the number that should stop you: this is not a capital-hungry medtech, it's a razor-and-blades franchise throwing off $378M FCF (14% FCF margin, growing) on $9.94B market cap — a 3.8% FCF yield with 25%+ topline growth. Insider activity shows actual open-market purchases on 2026-06-03 (6,240 shares bought vs 418 sold), not just option-award noise. That's a small but real signal at $143 after a 60% drawdown from $354.
Where I diverge from the prior stack: the synthesis "slight_upside" fair value of $149-159 is too timid given the trajectory. At 41x trailing PE the multiple looks rich in isolation, but trailing earnings are depressed by the FY24 tax-benefit comp base and margin-ramp quarters; forward earnings on FY26 run-rate (annualize Q1'26's $91M → $364M, plus continued margin expansion → likely $420-450M) put forward PE at 22-24x for a 25%+ grower with 42% ROIC. EV/EBITDA of 16.6x is frankly cheap for this quality profile. The pre-flight thesis that "the market is pricing in deceleration and share loss" is correct about market psychology but the data doesn't support the fear — Omnipod 5 sequential adds are still accelerating, and Tandem's Mobi hasn't materially dented growth. The Narrative Economics read of "steady-compounder, minimal narrative, anchored to fundamentals" is the most accurate of the prior outputs.
The contrarian case worth taking seriously: (1) GLP-1 disruption — if Ozempic/Zepbound-class drugs materially reduce Type 2 insulin dependence over 5-10 years, TAM erodes at the margin, though Type 1 (Omnipod's core) is untouched; (2) the Q1'26 sequential dip from $784M to $762M could mark the first genuine deceleration point rather than seasonality — worth watching Q2'26 closely; (3) gross margin of 71.6% is high for a device maker and could compress under payer pressure; (4) 41x trailing PE leaves no cushion if growth slips to 15% — the drawdown from $354 shows how violent the de-rating can be. The insider "buying" is 6,240 shares (~$900K) — meaningful but not table-pounding from a $10B company's executives. Data is also thin on segment breakout between US and international, where competitive dynamics differ. I dissent mildly with the synthesis's tepid framing: this is not a "signal-adjusted +11%" situation, it's a quality compounder that de-rated on a tax-comp optical issue and GLP-1 fear, with fundamentals still firing. Fair value on 25x forward earnings of $430M = $10.75B EV, or roughly $155-165/share near-term, with a real path to $190-200 if FY26 delivers >25% growth and 18%+ op margin. Downside to $115-120 if Q2'26 prints sub-20% growth. Risk/reward is asymmetric to the upside at $143.
GPT Reading
The raw numbers still read like a strong diabetes franchise, not a broken story. Revenue has gone from $1.10B in 2021 to $2.71B in 2025, a 2.5x increase in four years, and the quarterly run-rate is now roughly $3.0B annualized after $761.7M in the latest quarter. The year-over-year growth in the most recent quarter was 33.9% versus $569.0M, which is better than what a “maturing installed base” narrative would imply. Just as important, this is not growth bought with leverage or accounting tricks: the balance sheet holds $716.1M of cash against just $18.4M of debt, operating cash flow was $569.3M in 2025, and free cash flow was $377.7M even after a heavy $191.6M capex year. For a medical device company with recurring pod economics, that combination of 30%+ top-line growth, net cash, and real cash conversion is unusual.
What stands out most to me is that the market seems overly anchored to a margin wobble that looks more temporary than structural. 2025 annual net income of $247.1M was well below 2024’s $418.3M, but 2024 included an obviously unsustainably strong June quarter with $188.6M of net income on $488.5M of sales, a 38.6% margin, which skews the comparison. If I focus on the operating trajectory instead, it looks healthier: annual operating income rose from $308.9M in 2024 to $473.8M in 2025, and quarterly net margins recovered from 3.5% in June 2025 to 12.4%, 13.0%, and 12.0% in the next three quarters including the latest. That says the business likely absorbed a transitory cost step-up or launch/manufacturing inefficiency and is re-normalizing. A company growing revenue 31% on the annual numbers, carrying a 71.6% gross margin and 17.5% operating margin, should not be treated like a low-quality grower.
Valuation also looks more reasonable than the stock’s reputation suggests. At $9.94B market cap and $716M net cash, enterprise value is about $9.24B. Against 2025 revenue of $2.71B, that is 3.5x EV/sales; against operating income of $473.8M, it is under 20x EV/EBIT; against free cash flow of $377.7M, it is roughly 24x EV/FCF. For a business compounding revenue at 26% over several years with recurring consumable revenue and almost no financial risk, those are not demanding multiples. The P/E of 41x screens rich only because net income is the noisiest line here and was depressed relative to operating performance. If this business can sustain even mid-20s growth with low-teens net margins, today’s price does not look full; I get more comfortable thinking of fair value in the $165-$180 range than around the current $143.
The best argument against that view is that earnings quality may be less robust than the cash flow and revenue growth suggest. Recent earnings growth was negative 40.9% year over year despite 30.7% revenue growth, and annual net margin fell to 9.1% in 2025 from an inflated 20.2% in 2024. Gross margin at 71.6% is excellent, yet net margin remains modest for a company this scaled, which leaves room for bears to argue that manufacturing complexity, reimbursement pressure, and competition will cap incremental profitability. The latest quarter’s revenue of $761.7M was also down sequentially from $783.7M, and if growth is decelerating while margins settle only around 12%, then 41x earnings and 6.8x book are not obviously cheap. I take that seriously, but I weigh operating income growth, FCF generation, and the margin recovery over the last three quarters more heavily than one distorted annual net-income comparison.
What would change my mind is specific evidence that this is becoming a lower-quality medtech grower rather than a premium diabetes platform. If quarterly revenue growth slips below 20% while net margin fails to hold double digits, the current multiple support weakens fast. Likewise, if free cash flow drops materially below $300M despite continued revenue growth, I would conclude the capex and working-capital demands are more structural than I think. On the other hand, if the company prints another two quarters above $750M revenue with 12%-15% net margins, or shows annualized FCF moving toward $450M+, then the market’s caution at $143 will look misplaced.
Grok Reading
The numbers describe a scaled, high-quality insulin-delivery franchise that is still compounding at growth-stock rates while the market treats it like a decelerating specialty device name. Annual revenue climbed from $1.70B in 2023 to $2.07B in 2024 to $2.71B in 2025; the trailing four quarters sit near a $2.9B run-rate with Q1 2026 revenue of $761.7M still up roughly 34% versus the year-ago $569M. Gross margin holds at 71.6%, operating margin has expanded to 17.5%, ROIC prints an exceptional 42%, and free cash flow reached $377.7M on only $191.6M of capex against a nearly debt-free balance sheet ($18.4M debt, $716M cash). The 2025 net-income print of $247M looks weak versus 2024’s $418M, but that prior year was inflated by a one-time 38.6% margin quarter; recent quarters have re-stabilized at 12–13% net margins and a cleaner TTM earnings base closer to $300M. At $143—down roughly 60% from the $354 peak—the stock now trades at 41x trailing earnings, 3.8x sales and 16.6x EV/EBITDA, multiples that embed meaningful fear of growth collapse that the top-line data simply have not yet delivered.
What stands out is the divergence between still-robust unit economics and the market’s compression narrative. Recurring pod revenue gives the model SaaS-like characteristics inside a $15B-plus addressable diabetes market that remains under-penetrated by tubeless closed-loop systems. Operating cash flow of $569M and a current ratio of 2.8 leave ample capacity to fund both capacity and commercial expansion without leverage. Net insider purchases in June 2026 and a string of equity awards reinforce that management is not fleeing the valuation. The rule-based archetype of high-growth profitable fits: this is no longer a pre-profit story stock, and the narrative layer correctly scores intensity as minimal and mode as fundamentals-anchored. The prior valuation synthesis fair-value band of $149–$159 therefore looks directionally right; the stock sits modestly below even the unadjusted composite.
The strongest case against this read is straightforward and quantitative. Earnings CAGR of only 9.4% badly lags the 26% revenue CAGR, recent earnings are still down nearly 41% year-over-year, and the secondary signals flag both decelerating quarterly revenue trends and performance below sector benchmarks. A 41x P/E leaves little room if Omnipod 5 share gains slow or if reimbursement and manufacturing costs further compress the 9% net margin. Competitors with deeper balance sheets (Medtronic, Tandem) can force a slower, more price-competitive endgame, and the synthesis itself warns that methods disagree and that the market may still be pricing more growth than base-case models project—leaving the name vulnerable to any soft print. Macro headwinds add another layer of multiple risk. Those points justify why the stock is no longer at 70–80x; they do not, in my view, justify a further structural derating when FCF conversion is clean, leverage is negligible, and top-line growth remains above 30% on the most recent year-over-year comparison.
I would flip to neutral or outright cautious if two consecutive quarters show revenue growth falling through 15%, if gross margin breaches 68% on a sustained basis, or if forward guidance implies operating margin stalling below 15% while competitive win rates visibly deteriorate. Conversely, a clean re-acceleration above 25% growth with net margins holding the recent 12%+ zone would make the current $143 entry look clearly cheap relative to mid-teens earnings power on a larger base.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has scaled from $1.10B (2021) to $2.71B (2025), a ~25% CAGR, while gross margin expanded from 68.4% to 71.6% and operating margin climbed from 11.5% to 17.5%. This is genuine operating leverage: the 2022 dip (GM 61.7%, OpM 2.9%) was a real stumble but management restored and exceeded prior profitability. FCF inflected hard from -$180M in 2021 to +$377.7M in 2025, and OCF/NI of 5.17x with accruals at -1.8% of assets indicate reported earnings are backed by (and in 2025 conservatively lag) cash. Altman Z at 5.49 puts the balance sheet in the safe zone; $716M cash and $697.7M net cash mean no external funding dependency. Dilution discipline is acceptable, not elite: diluted shares went 68.6M to 71.9M (~1.2% CAGR), SBC is 2.3% of revenue, and buybacks only offset 23.3% of SBC - so per-share value is being modestly diluted, not compounded via repurchases. Insider tape shows two directors (Weatherman, Stonesifer) putting real money in on the same day (~$898K combined open-market purchases in June 2026), against only a small $60K sale - a genuine, if small, confidence signal. Net income dropped from $418M (2024) to $247M (2025) despite revenue and FCF rising, which warrants a look at tax or one-time items but is not a cash-quality issue.
Verify before trusting this (5)
- Why did 2025 net income fall to $247M from $418M in 2024 despite revenue and FCF rising - tax rate normalization, one-time 2024 benefit, or operating item?
- Customer/payor concentration and reimbursement exposure for Omnipod in the 10-K
- Competitive positioning vs tubed pumps and vs Medtronic/Tandem plus AID algorithm partnerships
- Any convertible debt or off-balance-sheet obligations behind the $18M gap between liquid cash and net cash
- Details of 2022 gross margin compression - supply chain, launch costs, or structural?
The e2e composite fair value of $149 implies ~4% upside from $143.34, and the signal-adjusted $159 implies ~11%. That is a rounding error, not a mispricing. The methods disagree sharply: DCF says $125 (below the price), EPV floor is $50 (a punishing steady-state number that flags how much of the value is growth-dependent), and an anchored P/E stretches to $215. Averaging methods that span 4x from floor to ceiling produces a composite that is more about method selection than genuine cheapness. The high-quality Company lens (score 58, clean OCF/NI 5.17x, FCF inflection) supports a deserved multiple above the DCF but not above where the stock already trades.
Verify before trusting this (5)
- Forward revenue guidance and Omnipod 5 attach rates in the next print - the whole DCF hinges on growth persistence
- Gross margin trajectory - pod manufacturing cost curve is the bear's main lever
- Any one-time items in the FCF inflection (working capital release vs sustainable conversion)
- Competitive updates from Medtronic 780G and Tandem Mobi that could compress deserved multiple
- Share count and SBC dilution disclosures to confirm the clean-issuance read
The macro tape is mildly supportive (risk-on, VIX 14, S&P near highs) and PODD's 1.1 beta means it participates in rallies, but the stock-specific sentiment is clearly negative right now. On Aug 5 the name crashed 20% after management trimmed full-year U.S. guidance on Type-2 onboarding execution problems, and the follow-up coverage (Q2 call recap, analyst 'must-read questions') is still relitigating that miss rather than moving on. That is the dominant force on this ticker this week. The steady-compounder narrative is intact but has taken a real crack: durability is being questioned at the exact seam bulls were leaning on (T2 TAM expansion). Narrative intensity was already 'minimal' with low cult coefficient, so there is no fan base to defend the stock into weakness; it trades on execution, and execution just wobbled. Analyst tone is in re-underwriting mode, which typically caps upside for several weeks post-cut. Offsets: it is a profitable medtech (defensive sector, lower macro-rate sensitivity than the average 1.1-beta name), the tape is calm, and the bear case is not a full narrative break, just a downgrade of pace. Net: a real, persistent headwind, but not a decisive one.
None surfaced.
None surfaced.
The world is converting chronic-disease management from manual dosing to closed-loop automation, and the constraint has shifted from technology to reimbursement and patient willingness to wear hardware. Tubeless, phone-controlled, pharmacy-dispensed delivery removes the two biggest adoption frictions at once, which is why Insulet compounds faster than a booming device category. Macro headwinds (10y at 4.63) matter little here: insulin delivery is non-discretionary and largely third-party paid, so the demand is not rate-sensitive. The genuine open question of the decade is whether metabolic pharmacology (GLP-1s) shrinks the future insulin-dependent population at the margin — a slow, partial offset that bites the type 2 expansion story rather than the type 1 core.
Prediction unavailable. valuation-synthesis has no result for PODD — the prediction needs its fair-value anchors.